EHA 2024 – Clemens Wendtner

Clemens Wendtner provides insights on treatment selection in CLL, emphasizing key principles for first-line therapy and summarizes the recent GAIA/CLL13 data comparing venetoclax combinations with chemoimmunotherapy in fit untreated patients. Additionally, he discusses factors guiding treatment choices in relapsed/refractory CLL and highlights the benefits of BTK inhibitors in indolent lymphomas.

Here is the full EHA 2024 report.